EN DE
Watch Cannabix Technologies Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cannabix Technologies Inc (BLOZF) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Cannabix Technologies Inc stock $0.14, price $0.26, that is 45.2% below the price, quality 40 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA13765L1013

CT Cannabix Technologies Inc logo Thin data Nov 10, 2026

Cannabix Technologies Inc

BLOZF · US
Very expensive, weak quality

Our calculation puts a fair price 45% below what the stock costs today.

Low debt
Quality 40/100
Fair value $0.1401 · Strongly overvalued
Weak Growth
Negative free cash flow
Trails peers (1/7)
Narrow moat 16/100 · thin data
Thin data
Estimate
Watch Cannabix Technologies Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.8200 $0.1270 Fair Value $0.1401 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.1270 – $0.8200 · fair‑value band $0.1051 – $0.1751 · the $0.2557 price screens above the $0.1401 fair value. As of Nov 10, 2026.

Follow Cannabix Technologies in your weekly email

Every Wednesday you see whether Cannabix Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cannabix Technologies Inc., a technology company, develops marijuana and alcohol breathalyzer technologies for employers, law enforcement, workplaces, and laboratories in the United States.

Show moreShow less

It offers Cannabix Marijuana Breath Test (MBT) for Tetrahydrocannabinol (THC) detection and quantification; Cannabix breath collection unit and breath cartridge for human breath sample collection, storage, and transportation.

The company also provides BreathLogix alcohol breathalyzer, an autonomous alcohol screening system that enables screening of employees, contractors, and visitors in mining, construction, and oil and gas industries; and BreathLogix Connect (BLC), a cloud platform that is designed for streamlining data.

It has a strategic partnership and development agreement with Omega Laboratories Inc. for the development and commercialization of the MBT technology. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014.

Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.

Stock analysis

Cannabix Technologies Inc (BLOZF) currently trades at $0.2557, while our estimate is $0.1401, 45% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.1051 (bear) to $0.1751 (bull), the price of $0.2557 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Cannabix Technologies Inc reported revenue of C$0 in FY2026 versus C$0 in FY2022. Reported net income was −C$5.8M in FY2026.

Key figures

Market cap $38.2M Micro · EPS (TTM) $−0.0200 · Return on equity −210% · Return on assets (EBIT) −109% (5-year average) · Revenue (TTM) $159K · Free cash flow −C$1.7M · Net cash C$876K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 60% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −45%, BLOZF screens richer than that median.

Fair Value

Bear $0.1051 Fair Value $0.1401 Bull $0.1751
Price $0.2557 · Downside -45.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 5
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 35
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

BLOZF screens overvalued: fair value 45% below the price. Compare with Abbott Laboratories, →

Compare Cannabix Technologies Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −45.2% · Bottom 25%
Profitability
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 30.43× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs BLOZF
DexCom, Inc DXCM $79.92 $89.18 +12% vs BLOZF
Stryker Corporation SYK $324.29 $358.30 +10% vs BLOZF
STERIS plc STE $257.12 $279.53 +9% vs BLOZF
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs BLOZF
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs BLOZF
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs BLOZF
Abbott Laboratories, ABT $110.46 $75.28 −32% vs BLOZF
Medtronic plc MDT $101.59 $65.61 −35% vs BLOZF
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs BLOZF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cannabix Technologies Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cannabix Technologies Inc Fair Value". https://www.fairvalue-calculator.com/stock/BLOZF

Frequently asked questions

Is Cannabix Technologies Inc (BLOZF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.1401 versus a price of $0.2557, about 45% lower (overvalued).
What is the fair value of BLOZF?
Our estimate for Cannabix Technologies Inc is $0.1401 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.2557.
What is the quality score of BLOZF?
Cannabix Technologies Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cannabix Technologies Inc (BLOZF)?
Our calculated price target is the estimate of $0.1401 (as of Nov 10, 2026). Cautious scenario $0.1051, optimistic scenario $0.1751. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cannabix Technologies Inc stock forecast for 2026?
Our estimate puts fair value at $0.1401, about 45% lower versus a price of $0.2557 (overvalued). Cautious scenario $0.1051, optimistic scenario $0.1751. The calculation is refreshed regularly with new filings.
What is the revenue of Cannabix Technologies Inc (BLOZF)?
Cannabix Technologies Inc reported trailing-twelve-month revenue of about $159K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Cannabix Technologies Inc (BLOZF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cannabix Technologies Inc it is $0.1401 per share (as of Nov 10, 2026), against a price of $0.2557.
Is Cannabix Technologies Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BLOZF trades above its calculated fair value: price $0.2557, fair value $0.1401, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLOZF?
No. The price is what the market pays today ($0.2557); the fair value is what the company's own numbers justify ($0.1401). For Cannabix Technologies Inc the two are $0.1156 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cannabix Technologies Inc worth?
The market values Cannabix Technologies Inc at about $38.2M (market capitalisation, as of Nov 10, 2026). Per share that is $0.2557; our models calculate a fair value of $0.1401 per share.
What do the bullish and bearish scenarios say about BLOZF?
Our models span a range for Cannabix Technologies Inc: cautious scenario $0.1051, base $0.1401, optimistic $0.1751 per share (as of Nov 10, 2026, price $0.2557). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cannabix Technologies Inc (BLOZF)?
Balance-sheet figures for Cannabix Technologies Inc (as of Nov 10, 2026): return on equity −209.9%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is BLOZF from its 52-week high?
Cannabix Technologies Inc trades at $0.2557, about 60% below its 52-week high of $0.6400 and 25% above the low of $0.2040 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1401 is for.
Which stocks are comparable to Cannabix Technologies Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cannabix Technologies Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.2557, calculated fair value $0.1401 (−45%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Cannabix Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cannabix Technologies Inc (BLOZF)?
The closing price on Nov 10, 2026 was $0.2557. Our estimate is $0.1401, about 45% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cannabix Technologies Inc right now?
The price sits above even our optimistic bull case ($0.1751). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Cannabix Technologies Inc

How large is the market capitalisation of Cannabix Technologies Inc (BLOZF)?
The market capitalisation of Cannabix Technologies Inc is $38.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cannabix Technologies Inc (BLOZF)?
Earnings per share at Cannabix Technologies Inc are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cannabix Technologies Inc (BLOZF)?
The return on equity (ROE) of Cannabix Technologies Inc is −210% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cannabix Technologies Inc (BLOZF)?
On an EBIT basis the return on assets of Cannabix Technologies Inc is −109% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Cannabix Technologies Inc (BLOZF) generate?
The free cash flow of Cannabix Technologies Inc is −C$1.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cannabix Technologies Inc (BLOZF) hold?
Cannabix Technologies Inc holds more cash than debt, C$876K net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cannabix Technologies Inc in the live analysis

One click puts Cannabix Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.